{"analyses":[{"ciLowerLimit":"0.296","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.553","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.","paramType":"Hazard Ratio (HR)","paramValue":"0.404","statisticalMethod":"Log Rank","testedNonInferiority":false},{"ciLowerLimit":"0.363","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.688","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.","paramType":"Hazard Ratio (HR)","paramValue":"0.499","statisticalMethod":"Log Rank","testedNonInferiority":false},{"ciLowerLimit":"0.630","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.085","groupIds":["OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.169","pValueComment":"The p-value is based on unstratified log rank test of Kaplan Meier curve differences between the treatment groups.","paramType":"Hazard Ratio (HR)","paramValue":"0.827","statisticalMethod":"Log Rank","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not estimable because of the number of participants who had not started a non-protocol anti-myeloma therapy at data cut-off.","groupId":"OG000","lowerLimit":"99.86","upperLimit":"NA","value":"128.9"},{"groupId":"OG001","lowerLimit":"60.14","upperLimit":"76.00","value":"66.1"},{"groupId":"OG002","lowerLimit":"61.14","upperLimit":"72.43","value":"66.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"152"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"154"}],"units":"Participants"}],"description":"Data as of 11 May 2010 cutoff. Time to the next antimyeloma therapy was defined as time from randomization to the start of another non-protocol antimyeloma therapy. Participants who do not receive another anti-myeloma therapy were censored at the last assessment or follow-up visit known to have received no new therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10 mg (MPR) for up to 9 cycles, followed by maintenance therapy with single-agent lenalidomide (R) 10mg from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG000","title":"MPR+R"},{"description":"Double-blind induction therapy with melphalan/prednisone and lenalidomide 10mg (MPR) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG001","title":"MPR+p"},{"description":"Double-blind induction therapy with melphalan/prednisone and placebo (MPp) for up to 9 cycles, followed by maintenance therapy with placebo (p) from cycle 10 to disease progression. Optional open-label extension therapy with lenalidomide up to 25 mg for participants with progressive disease.","id":"OG002","title":"MPp+p"}],"paramType":"MEDIAN","populationDescription":"Intent to treat population","reportingStatus":"POSTED","timeFrame":"Up to 168 weeks","title":"Kaplan Meier Estimates for Time to Next Antimyeloma Therapy","type":"SECONDARY","unitOfMeasure":"weeks"}